Comorbidities of Bladder pain syndrome/interstitial cystitis: A population-based study

School of Public Health, Taipei Medical University Department of Urology, Taipei County Hospital School of Health Care Administration, Taipei Medical University, Taipei, Taiwan.
BJU International (Impact Factor: 3.53). 09/2012; 110(11C). DOI: 10.1111/j.1464-410X.2012.11539.x
Source: PubMed


Study Type – System prevalence (cohort)
Level of Evidence 2a
What's known on the subject? and What does the study add?
Compared with the general population, patients with BPS/IC often experience difficulties in performing normal activities owing to physical limitations, decreased energy, greater pain and impaired social functioning
With the exception of metastatic cancer, separate conditional logistic regression analyses in this study suggested that subjects with BPS/IC were consistently more likely than subjects without BPS/IC to have all the medical comorbidities investigated. When compared with subjects without BPS/IC, subjects with BPS/IC had particularly higher odds of comorbid neurological diseases, rheumatological diseases and mental illnesses.

24 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: MicroRNAs (miRNAs), a novel class of molecules regulating gene expression, have been hailed as modulators of many biological processes and disease states. Recent studies demonstrated an important role of miRNAs in the processes of inflammation and cancer, however, there are little data implicating miRNAs in peripheral pain. Bladder pain syndrome/interstitial cystitis (BPS/IC) is a clinical syndrome of pelvic pain and urinary urgency/frequency in the absence of a specific cause. BPS is a chronic inflammatory condition that might share some of the pathogenetic mechanisms with its common co-morbidities inflammatory bowel disease (IBD), asthma and autoimmune diseases. Using miRNA profiling in BPS and the information about validated miRNA targets, we delineated the signaling pathways activated in this and other inflammatory pain disorders. This review projects the miRNA profiling and functional data originating from the research in bladder cancer and immune-mediated diseases on the BPS-specific miRNAs with the aim to gain new insight into the pathogenesis of this enigmatic disorder, and highlighting the common regulatory mechanisms of pain and inflammation.
    Cellular and Molecular Life Sciences CMLS 03/2013; 70(20). DOI:10.1007/s00018-013-1275-7 · 5.81 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Vascular factors are proposed in the etiology of bladder pain syndrome/interstitial cystitis (BPS/IC). In this study, we investigated the risk of stroke among women following a diagnosis of BPS/IC over 3 years of follow-up, compared to controls without a BPS/IC diagnosis. This retrospective cohort study used data retrieved from the Taiwan "Longitudinal Health Insurance Database 2000." We identified 847 women who received a diagnosis of BPS/IC between January 1, 2001 and December 31, 2008 (study group) and 4,235 comparison women (women without a BPS/IC diagnosis matched on age and other selected demographic variables. All subjects were tracked for 3 years following the index date to identify those who received a diagnosis of stroke during follow-up. The stroke incidence rate was 20.86 (95% confidence interval (CI): 15.78-27.07) and 11.65 (95% CI: 9.88-13.64) per 1,000 person-years among the study and comparison cohorts, respectively. Cox regression analysis showed a stroke hazard ratio (HR) of 1.52 (95% CI: 1.09-2.14) in the BPS/IC group relative to the comparison group over 3-year follow-up, after adjusting for hypertension, diabetes, coronary heart disease, atrial fibrillation, hyperlipidemia, and chronic kidney disease. The adjusted HR of ischemic stroke was 1.52 (95% CI: 1.02-2.27). However, there was no significant difference between the two groups in hemorrhagic stroke risk. Our study demonstrates an association between BPS/IC and a subsequent ischemic stroke diagnosis among women in Taiwan. Neurourol. Urodynam. © 2013 Wiley Periodicals, Inc.
    Neurourology and Urodynamics 10/2013; 26(2). DOI:10.1002/nau.22515 · 2.87 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Bladder pain syndrome is one of the most challenging urological disorders to diagnose and manage. Symptoms can be highly debilitating for patients. The exact etiology remains unclear although there have been associations with other regional and global functional disorders. The magnitude and duration of symptom response to current therapies can be highly variable amongst patients, and even within an individual patient’s course. A multidisciplinary approach is paramount and optimal therapy may involve multiple simultaneous treatments.
    Current Bladder Dysfunction Reports 03/2014; 9(1). DOI:10.1007/s11884-013-0214-7
Show more